Effect of gout and diabetic kidney disease on renal cancer development in Korea
Clinical Kidney Journal · 01.08.2024 · 17 (8)
DOI: 10.1093/ckj/sfae171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 28.06.2024. Verfasst von Seung Min Chung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Bio & Medical Technology Development Program, National IT Industry Promotion Agency.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) and gout are risk factors for renal cancer. We analysed the effects of comorbid diabetic kidney disease and gout on renal cancer.
Methods
This retrospective cohort study enrolled 847 884 patients with type 2 diabetes mellitus (T2DM) who underwent health assessments provided by the Korean National Health Insurance Service in 2009. Based on CKD occurrence (glomerular filtration rate <60 ml/min/1.73 m2) and gout (two outpatient visits or one hospitalization within 5 years), patients were classified into four groups: CKD−Gout− (87.5%), CKD−Gout+ (2.5%), CKD+Gout− (9.3%) and CKD+Gout+ (0.7%). Patients with incident renal cancer (International Classification of Diseases code C64) were followed up until December 2018.
Results
Renal cancer was diagnosed in 2376 patients (0.3%). Renal cancer incidence increased in sequential order of CKD−Gout− [0.29/1000 person-years (PY), CKD+Gout− and CKD−Gout+ (0.44 and 0.48/1000 PY, respectively) and CKD+Gout+ (1.14/1000 PY). Comorbid gout increased renal cancer risk depending on CKD occurrence {hazard ratio [HR] 1.28 [95% confidence interval (CI) 1.04–1.58 among those without CKD; HR 1.95 [95% CI 1.45–2.63] among those with CKD; P-value for interaction = 0.024}. The interaction was significant, particularly in men and patients with a shorter diabetes duration (<5 years) and lesser medication use (no insulin or fewer than three classes of oral hypoglycaemic agents).
Conclusions
CKD and gout individually contributed to renal cancer incidence, and the risk is further increased when gout coexists with CKD. Screening for gout and appropriate management of CKD at an early T2DM stage may be beneficial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
ORCID-Profile: Seung Min Chung, Da Young Lee, Nan Hee Kim
Förderung
- National Research Foundation of Korea
- Bio & Medical Technology Development Program
- National IT Industry Promotion Agency
- Development of AI Precision Medical Solution
- Korea Health Industry Development Institute
Zitieren
APA
Chung, S. M., Jung, I., Lee, D. Y., Park, S. Y., Yu, J. H., Moon, J. S., Seo, J. A., Han, K., & Kim, N. H. (2024). Effect of gout and diabetic kidney disease on renal cancer development in Korea. Clinical Kidney Journal, 17(8). https://doi.org/10.1093/ckj/sfae171
Vancouver
Chung SM, Jung I, Lee DY, Park SY, Yu JH, Moon JS, et al. Effect of gout and diabetic kidney disease on renal cancer development in Korea. Clinical Kidney Journal. 2024;17(8). doi:10.1093/ckj/sfae171
BibTeX
@article{Chung2024,
author = {Chung, Seung Min and Jung, Inha and Lee, Da Young and Park, So Young and Yu, Ji Hee and Moon, Jun Sung and Seo, Ji A and Han, Kyungdo and Kim, Nan Hee},
title = {Effect of gout and diabetic kidney disease on renal cancer development in Korea},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {8},
doi = {10.1093/ckj/sfae171}
}
EUVIMED